Published in Cancer Weekly, July 6th, 2004
The presentation was made at the 40th annual meeting of the American Society of Clinical Oncology (ASCO), held in New Orleans, Louisiana.
This multicenter, randomized study enrolled 45 stage IIIb or stage IV advanced lung cancer patients who were to receive weekly dosing of squalamine, combined with weekly chemotherapy of carboplatin and paclitaxel. All 45 patients were evaluated for safety. Overall, the combined drug regimen was well-tolerated, with fewer serious...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.